期刊文献+

恩度联合TP方案及单纯TP方案治疗晚期非小细胞肺癌的疗效比较 被引量:2

下载PDF
导出
摘要 目的观察恩度联合TP方案治疗晚期非小细胞肺癌的临床效果。方法将40例晚期非小细胞肺癌随机分为2组。治疗组给予恩度+TP方案治疗,对照组仅给予常规TP方案化疗。治疗结束后评价疗效,并统计分析不良反应。结果治疗组临床有效率为65%,临床获益率为80%;对照组临床有效率为50%、临床获益率为65%。两组比较差异无统计学意义(P>0.05)。骨髓抑制、肝肾功能异常以及胃肠道反应是最为常见的不良反应,治疗组不良反应总发生率为85%,对照组不良反应总发生率为90%。两组比较无统计学差异。结论恩度联合TP方案治疗晚期非小细胞肺癌疗效与单纯TP方案比较没有优势。
作者 刘少平
机构地区 江阴市人民医院
出处 《山东医药》 CAS 北大核心 2011年第21期54-55,共2页 Shandong Medical Journal
  • 相关文献

参考文献3

  • 1曾大雄,徐永健.非小细胞肺癌的化疗进展[J].世界临床药物,2009,30(4):242-247. 被引量:10
  • 2Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Expt Cell Res,2006,312(5):594-607.
  • 3Ling Y,Yang Y,Lu N,et al.Endostar,a novel recombinant human endostatin,exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/FIK-1 of endothelial cells[J].Biochem Biophys Res Commun,2007,361(1):79-84.

二级参考文献10

  • 1Anglim PP,Alonzo TA,Laird-Offringa IA.DNA methylation-based biomarkers for early detection of non-small cell lung cancer:an update[].Molecular Cancer.2008
  • 2Scagliotti G,Pastorino U,Vansteenkiste J,et al.A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer(NSCLC):Follow up data of Ch.E.S.T[].Journal of Clinical Oncology.2008
  • 3Le Chevalier T,Dunant A,Arriagada R,et al.Long-term results of the International Adjuvant Lung Cancer Trial(IALT)evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer(NSCLC)[].Journal of Clinical Oncology.2008
  • 4Strauss GM,Herndon JE2nd,Maddaus MA,et al.Adjuvant paclitaxel plus carboplatin compared with observation in stageⅠB non-small-cell lung cancer:CALGB9633with the Cancer and Leukemia Group B,Radiation Therapy Oncology Group,and North Central Cancer Treatment Group Study Groups[].Journal of Clinical Oncology.2008
  • 5Blumenschein GR,Paulus R,Curran WJ,et al.A phaseⅡstudy of cetuximab(C225)in combination with chemoradiation(CRT)in patients(PTS)with stageⅢA/B non-small cell lung cancer(NSCLC):A report of the2year and median survival(MS)for the RTOG0324trial[].Journal of Clinical Oncology.2008
  • 6Govindan R,Bogart J,Wang X,et al.A phaseⅡstudy of pemetrexed,carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer:CALGB30407—Early evaluation of feasibility and toxicity[].Journal of Clinical Oncology.2008
  • 7El-Shenshawy HM,Fathy A,Eteba S,et al.Sequential chemoradiotherapy versus concurrent chemoradiotherapy plus consolidation chemotherapy in unresectable stageⅢnon-small cell lung cancer[].Journal of Clinical Oncology.2008
  • 8Azim HA Jr,Elattar I,Loberiza FR Jr,et al.Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer:A systematic overview[].Lung Cancer.2008
  • 9Heymach JV,Paz-Ares L,de Braud F,et al.Randomized phaseⅡstudy of vandetanib alone or with paclitaxel and carboplatin as fi rst-line treatment for advanced non-small-cell lung cancer[].Journal of Clinical Oncology.2008
  • 10Douillard JY,Hirsh V,Mok T,et al.Molecular and clinical subgroup analyses from a phaseⅢtrial comparing Gefi tinib with docetaxel in previously treated non-small-cell lung cancer[].Journal of Clinical Oncology.2008

共引文献9

同被引文献14

  • 1Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance,epidemiologic, and end results database[J]. J Clin Oncol, 2006, 24(28) : 4 539.
  • 2Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review[J]. Ann Oncol, 1999, 10 (7) : 753.
  • 3美国国家综合癌症网络.2011非小细胞肺癌临床实践指南:中国版[EB/OL].(2011—04—15)[2012—12—19].http://www.nccn—asia.org/.
  • 4Eisenhauer EA, Therasse P, Bogaerts J, et al. New resp- onse evaluation criteria in solid tumours: revised RECIST guideline: version 1.1[J]. Eur J Cancer, 2009, 45 (2) : 228.
  • 5马军,秦叔逵,张清媛.中国临床肿瘤学教育专辑:2007[M].哈尔滨:黑龙江科学技术出版社,2007:232—239.
  • 6Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006,312 (5):594.
  • 7Li B, Wu X, Zhou H, et al. Acid-induced unfolding mec- hanism of recombinant human endostatin[J]. Biochemis- try, 2004,43(9):2 550.
  • 8Lu N, Ling Y, Gao Y, et al. Endostar suppresses inva- sion through downregulating the expression of matrix me- talloproteinase-2/9 in MDA-MB-435 human breast cancer cells[J]. Exp Biol Med, 2008,233(8) : 1 013.
  • 9Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts[J].AmJPathol, 2004,165(1) :35.
  • 10Wilson RF, Morse MA, Pei P, et al. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells[J]. Anticancer Res, 2003,23 (2B) : 1 289.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部